DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
SNX-5422 is an investigational drug.
There have been 16 clinical trials for SNX-5422. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2006.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Stomatitis. The leading clinical trial sponsors are Esanex Inc., Serenex, Inc., and National Cancer Institute (NCI).
Recent Clinical Trials for SNX-5422
|Safety and Activity of SNX-5422 Plus Ibrutinib in CLL||Esanex Inc.||Phase 1|
|Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL||Esanex Inc.||Phase 1|
|Study of SNX-5422 in TP53 Null Cancers||Esanex Inc.||Phase 2|